InvestorsHub Logo
Followers 11
Posts 1093
Boards Moderated 0
Alias Born 02/20/2015

Re: Couch post# 257696

Tuesday, 05/23/2017 2:22:46 PM

Tuesday, May 23, 2017 2:22:46 PM

Post# of 401117

Nasrat clearly brushed off our present generics as breadcrumbs, which means he didn't have much interest in them. Now he brings in another breadcrumbs generic for Elite but is also one that earns him side money apart from his responsibilities to Elite and Elite shareholders. That's bizarre and questionable at the very least. What concrete good does this do for Elite shareholders? Please no pie-in-the-sky generalizations about this somehow improves our standing with the FDA.

At best, this move doesn't seem to have any ability to increase Elite shareholder value. If true, that should mean the CEO of the company really shouldn't have done it bc his responsibility is to make moves to increase shareholder value.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News